B Activation
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
Abstract |
|---|
|
|
|---|
Prolonged eosinophil survival, i.e., reduced apoptosis, is implicated in the pathogenesis of chronic allergic inflammation. Here we demonstrate that interleukin (IL)-15, in the presence or absence of tumor necrosis factor (TNF)-
, reduces spontaneous apoptosis in freshly isolated human eosinophils. The prosurvival effect of IL-15 was abrogated by neutralizing antibody
to granulocyte macrophage-colony stimulating factor (GM-CSF), although GM-CSF was not detected in conditioned media
by ELISA. Additionally, the effect of IL-15 on spontaneous eosinophil apoptosis appeared to require nuclear factor-
B (NF-
B)
activation based on evidence for NF-
B nuclear translocation
and abrogation of the effect by the NF-
B inhibitor, Bay 11-
7082. Finally, the data demonstrate that IL-15 expression is
higher in the submucosa of endobronchial tissues from subjects
with moderate to severe asthma when compared with control
subjects. Thus, our results suggest that IL-15, either alone or in
combination with TNF-
, may perpetuate allergic inflammation by reduction of spontaneous eosinophil apoptosis through autocrine production of GM-CSF and NF-
B activation.
| |
Introduction |
|---|
|
|
|---|
Prolonged eosinophil survival, i.e., reduced apoptosis, is implicated in the pathogenesis of chronic allergic inflammation (1). Eosinophil apoptosis, similar to that of other cells, is regulated by a variety of cytokines and cell surface receptors in a multistep process. The classic hematopoietins, interleukin (IL)-3, IL-5, and granulocyte macrophage-colony stimulating factor (GM-CSF), constitute a cytokine family well known to inhibit apoptosis in these cells (4). The signaling pathways for IL-5 and GM-CSF have been partially delineated and found to be dependent on phosphorylation of Lyn and Syk and activation of p21 Ras/Raf-1, Jak-2/Stat, and PI3 kinase pathways (7, 8). Although IL-5, produced by T cells and to a lesser extent eosinophils, is the most specific cytokine for eosinophils, GM-CSF is widely expressed by human myofibroblasts, endothelial cells, airway epithelial cells, and eosinophils themselves, suggesting a potentially important role as both an autocrine and paracrine factor (4, 9). Moreover, GM-CSF production has been shown to be greater in asthmatic airways when compared with controls, and correlates with both the frequency of nonapoptotic eosinophils and macrophages in bronchial biopsy specimens and the severity of asthma (2). These findings underscore the importance of GM-CSF and IL-5 on eosinophil apoptosis in vivo.
Aside from these well-recognized hematopoietins, the
family of common
chain-sharing cytokines present in diseases presumed to have a Th2 lymphocyte involvement has
also been investigated for its effects on eosinophil survival
and functions. IL-2 has been shown to neither prolong nor
reduce eosinophil survival. IL-4, a significant Th2 cytokine
in allergic diseases, has been shown to induce eosinophil
accumulation but, surprisingly, may enhance apoptosis in
eosinophils from normal and atopic dermatitis subjects (12).
IL-9 has been reported by others to inhibit eosinophil apoptosis via upregulation of IL-5 receptor mRNA (13). IL-13 modestly prolonged eosinophil survival and upregulated
the expression of CD69 cell surface protein and mRNA expression (14). Of great interest to our investigation, IL-15 has
been shown to prolong NK cell, intestinal intraepithelial
lymphocyte, synovial T cell, and neutrophil survival (15-
18). Although effects on other cells have been investigated, the role of IL-15 in eosinophil survival has not yet
been established. Notably, IL-15 mRNA is expressed in most
tissues, with high levels observed in skeletal muscle, placenta, heart, spleen, liver, kidney, dermal layers of skin, and
lung (19), in contrast to the expression IL-2 mRNA, the cytokine it most closely mimics, which is limited to activated T cells and to tissues that contain T cells. A role for IL-15 in allergic diseases has been proposed, as IL-15 induced allergen-specific human T cells to produce IL-5, and
when combined with IL-18, induced production of GM-CSF from human NK cells (20, 21). Moreover, a patient
with hypereosinophilic syndrome has recently been described as having elevated serum levels of IL-15 (22). From
these data, we hypothesize that IL-15 produced at the site
of allergic inflammation might play a role in recruitment, activation, and survival of eosinophils. In this study, we provide data to suggest that IL-15 regulates eosinophil apoptosis
in vitro via autocrine production of GM-CSF. We also demonstrate that nuclear factor (NF)-
B activation is required
for IL-15 to exert this effect. Moreover, IL-15 is shown to
be present in asthmatic airways. These findings suggest potential involvement of IL-15 in allergic diseases.
| |
Materials and Methods |
|---|
|
|
|---|
Eosinophil Donor Information
Peripheral blood was obtained by venipuncture from 21 different patients with allergic rhinitis or asthma. Subjects were between the ages of 18 and 40, and in otherwise good health. No oral, inhaled, or intranasal corticosteroids were allowed for the previous 4 wk, antihistamines for the previous 5-7 d (long-acting) or 24 h (short acting), and no nonsteroidal anti-inflammatory drugs, antilipid drugs, or ethanol for 48 h before donation. All subjects were nonsmokers, and subjects had not donated blood within the preceding 8 wk. Informed consent was obtained according to a protocol approved by the National Jewish Research and Medical Center IRB Committee.
Eosinophil Isolation and Culture
Eosinophils were purified using a negative immunomagnetic procedure. Briefly, heparinized whole blood was centrifuged (1,000 × g,
30 min) over a Percoll density gradient (density 1.090 g/ml; Pharmacia Biotech, Piscataway, NJ) to separate mononuclear cells from
granulocytes. After removal of the mononuclear cell band, erythrocytes were lysed by incubation (2× for 30 s) with sterile, cold
water. The remaining white blood cells were incubated with 200 µl
of anti-CD16, 100 µl of anti-CD3, and anti-CD14-coated microbeads (Miltenyi Biotec, Auburn, CA) for 60 min and were then passed through steel mesh columns that had been previously washed with PEB (phosphate-buffered saline with 5 mM ethylenediamine tetraacetic acid and 0.5% human serum albumin). The cells in the eluent were stained and examined microscopically. Purity of eosinophils in all experiments was > 99%. After isolation, eosinophils
were transferred to 5 ml polypropylene round-bottom tubes in
1-ml aliquots (0.5 million/ml) in Iscove's medium (GIBCO BRL,
Grand Island, NY) with 20% fetal calf serum (Hyclone, Logan,
UT). Eosinophils were variously stimulated with 100 U/ml of recombinant human tumor necrosis factor (TNF)-
(Genzyme,
Cambridge, MA), IL-2 (5 ng/ml), IL-4 (5 ng/ml), IL-15 (50 ng/ml)
(Pepro Tech Inc., Rocky Hill, NJ), or GM-CSF (100 pg/ml). The
concentration of cytokines was chosen from prior titrations (data
not shown) of IL-2, IL-4, and IL-15 from 1-100 ng/ml, with or
without TNF-
, which showed that IL-2 and IL-4, with or without TNF-
, did not appear to exhibit a dose-dependent response.
The maximal effect of IL-15, with or without TNF-
, was seen at
25 ng/ml. For blockade of NF-
B activity, eosinophils were incubated with Bay 11-7082 (3 µm), an inhibitor of I
B phosphorylation (CalBiochem, San Diego, CA) at 37°C for 30 min before the
addition of cytokines. For antibody neutralization of cytokine
activity, purified mouse monoclonal anti-human IL-3, IL-5, and
GM-CSF antibodies (IgG1) (Genzyme, Cambridge, MA) (50 µg/ml)
were added immediately to unstimulated and stimulated eosinophils. Culture with isotype control antibody had no effect on
eosinophils. Cultures were maintained at 37°C in a 5% CO2 environment. Every effort was made to minimize exposure to lipopolysaccharide (LPS) during eosinophil isolation and culture.
Human serum albumin and fetal calf serum were screened for
LPS by limulus amebocyte lysate kit (Associates of Cape Cod,
Woods Hole, MA): contamination with LPS was less than 25 and
6 pg/ml, respectively.
Assessment of Eosinophil Viability and Apoptosis
Eosinophils were gently vortexed and then removed from each tube at 24, 48, and 72 h. Viability of eosinophils was then assessed at these different time points by trypan blue exclusion. Those eosinophils that excluded trypan blue after a 5-min incubation were considered viable cells. At least 100 eosinophils were counted under the light microscope. Apoptosis was assessed by light microscopy following Kimura staining on the basis of cells exhibiting classic apoptotic morphology: nuclear and cytoplasmic condensation. Flow cytometric analysis of hypodiploid DNA based on propidium iodide staining in a FACSCaliber Flow cytometer (Becton Dickson, Franklin Lakes, NJ) was also used to verify apoptosis. All three methods were highly correlated, with nuclear morphology showing the earliest evidence of apoptosis, followed by DNA fragmentation and loss of trypan blue exclusion. All data are presented as mean ± SEM. Significant differences between groups were determined by one-way analysis of variance (ANOVA) (JMP software program; SAS Institute, Cary, NC). If the overall P value was less than 0.05, the Tukey's test was then used to confirm differences in individual groups. A P value of < 0.05 was considered significant in all cases.
Enzyme-Linked Immunosorbent Assay Measurements
For cytokine measurements, eosinophils were cultured at 2 × 106/ml for 24 to 48 h. This increased cell density did not alter the
effects of cytokines on viability. Cells were then pelleted by a 10-min centrifugation at 4°C and the supernatants carefully removed
and immediately frozen at
70°C for analysis of cytokine production. Cytokine enzyme-linked immunosorbent assays (ELISAs) were performed according to the manufacturer's instructions
(Pharmingen, San Diego, CA). OptEIA reagents were used for
these ELISAs and sensitivity was ~ 7 pg/ml.
p65 Nuclear Translocation by Confocal Microscopy
Immunostaining was performed as described by Thomassen and
colleagues (23). Briefly, eosinophils were resuspended at 1 × 106
cells/ml. IL-15, TNF-
, GM-CSF, and Bay 11-7082 were added
as in the apoptosis studies described previously. After 15 min,
samples were placed on ice, cytospun, and fixed in acetone for 30 s.
Cells were then permeablized and blocked in 0.1% Triton plus
2% goat serum for 30 min. Samples were then incubated with 1 µg
of rabbit polyclonal antibody against human p65 (Santa Cruz
Biotech, Santa Cruz, CA) overnight at 4°C after which they were
washed twice and chromotrope-2R (0.2%) added for 30 min to
block nonspecific granular staining by secondary antibody as described by Dewson and colleagues (24). Samples were washed
twice and 1 µg of Cy3 goat anti-rabbit and 10 µM DAPI added
for 1 h, at which point they were washed twice, mounted, and imaged under oil using a Leica microscope (Leica Inc., Deerfield, IL)
and Slidebook software (Denver, CO). Eosinophils were serially
sectioned, and deconvolved images were obtained from equatorial sections. Isotype control antibody staining was performed
and was negligible.
Immunohistochemical Staining of IL-15 in Endobronchial Biopsies
Endobronchial biopsies were obtained from subjects with asthma
and nonatopic normal subjects. All asthmatic subjects met the American Thoracic Society criteria for asthma. Among the 13 subjects with asthma, 2 were classified as moderate and 11 as severe asthmatics. Moderate asthmatics had an FEV1 of < 80%
predicted, were on
-agonists and inhaled corticosteroids or
theophylline, and did not have a history of urgent health care utilization or oral corticosteroid use. Subjects with severe asthma
were patients referred to our institute for severe, oral corticosteroid-dependent asthma with frequent hospitalization and emergency room visits. Normal control subjects (n = 5) had no history
of respiratory diseases and were on no medications. The protocol
was approved by the institutional review board, and all subjects
gave informed consent. Briefly, specimens were fixed in acetone
at
20°C overnight and then embedded in glycol methacrylate
resin. Tissue blocks were stored at
20°C. Serial 2-µM sections
were cut from well-oriented tissue blocks with a Reichert Ultracut E ultramicrotome (Leica).
Tissue sections were stained using goat antibody against human IL-15 (R&D Systems, Inc., Minneapolis, MN). A three-step indirect immunostaining method was used. Sections were treated with 0.3% hydrogen peroxide in 0.05 M Tris-buffered saline (TBS) (pH 7.6) for 30 min to inhibit endogenous peroxidase, followed by incubation with 1% normal goat serum for 30 min to block potential nonspecific binding sites. The slides were then incubated with primary antibody for 2 h at room temperature, followed by incubation with biotinylated rabbit anti-goat IgG for 1 h at room temperature. Thereafter, avidin-biotin-peroxidase complex (Vecter Labs, Burlingame, CA) was added to the slides for 45 min at room temperature. After rinsing the slides in TBS, 0.03% aminoethylcarbazole (AEC) in 0.03% hydrogen peroxide was used as a substrate to develop a peroxide-dependent red color reaction. Slides then were counterstained with Mayer's hematoxylin and covered with Crystalmount (Biomeda Corp., Foster City, CA). Appropriate control slides were similarly treated but with the primary antibody replaced by nonimmune serum or TBS. One slide from each tissue block was stained with hematoxylin-eosin for routine histology.
Analyses of IL-15-Positive Cells
A National Institutes of Health (NIH) scion image analysis program was used to measure the submucosa area, which included the subepithelial basement membrane (SBM), and deeper submucosa was defined as the area between the external side of the SBM and the internal side of the smooth muscle and/or mucous glands. Blood vessels, smooth muscle, and mucous glands were excluded. Nucleated cells positive for IL-15 were counted at ×400 magnification (measured area, 0.5 [range 0.3-0.7] mm2). The cell count was expressed as number of cells/mm2. Comparisons between tissues from subjects with asthma and normal controls were made using the Wilcoxon Rank Sum test and group data expressed as medians ± interquartile range (IQR). The observer was blinded to the clinical state of the subjects.
Double-Immunofluorescent Staining
To identify the cellular sources of IL-15-positive cells in the submucosa of endobronchial biopsy tissue, double-immunofluorescent staining was performed in two subjects with severe asthma. Tissue sections were incubated with a mixture of a mouse monoclonal cell marker antibody and a goat polyclonal IL-15 antibody, followed by incubation with a mixture of FITC-conjugated anti-goat and rhodamine-conjugated anti-mouse secondary antibodies (Dako, Carpinteria, CA). The slides were mounted and observed with an Olympus BX51 immunofluorescence microscope. Control slides were similarly treated but with the primary antibodies replaced by nonimmune goat serum and mouse IgG.
| |
Results |
|---|
|
|
|---|
Inhibition of Spontaneous Eosinophil Apoptosis
IL-15 was assessed for its ability to modulate eosinophil
survival in vitro, and its effects were contrasted to those of
the other common
chain receptor-sharing cytokines.
Culture of control eosinophils was followed by a loss in
viability determined by trypan blue exclusion in a time-dependent fashion (Figure 1A). In contrast to IL-2 and IL-4,
which had only modest effects, IL-15 significantly enhanced eosinophil survival when compared with controls,
and the effect was most pronounced at 72 h (59.5 ± 5.9% versus 23.2 ± 3.6%, P < 0.0001). Additionally, the effect
of costimulation with TNF-
on eosinophil survival was
examined, as it is often present in the Th2 milieu and plays
a pivotal role in regulation of apoptosis in other cell types.
While TNF-
alone appeared to have a modest effect on
prolonging eosinophil survival, as previously reported (25),
TNF-
only slightly augmented the pro-survival effect seen
from IL-15 alone (Figure 1B). Of note, when TNF-
was
combined with IL-4, a significant prosurvival effect (which was not seen with IL-4 alone) became evident (67.8 ± 3.8 versus 23.2 ± 3.6 for controls, P < 0.0001). Although the
combination of TNF-
and IL-2 appeared to enhance eosinophil viability (versus controls), the effect was not different
than that seen from TNF-
alone (P = 0.26).
|
Loss of viability in these cultures was due to apoptosis
as confirmed by DNA fragmentation assessed by flow cytometry and by examination of nuclear morphology (Figure 2). The number of cells exhibiting hypodiploid DNA
was significantly reduced (P < 0.001, n = 5) in eosinophils
cultured with IL-15 alone or in combination with TNF-
(Figure 2, top panel). This was in contrast to IL-4 (shown)
and IL-2 (not shown), which did not alter spontaneous eosinophil apoptosis when compared with controls. TNF-
by itself modestly reduced the amount of hypodiploid
DNA. As above, the combination of TNF-
and IL-4 inhibited DNA fragmentation to the same degree as IL-15.
By contrast, the effect of IL-2 in combination with TNF-
was not significantly different than that seen with TNF-
alone (data not shown). Similar results were obtained with Kimura staining of cells, showing significantly fewer pyknotic nuclei in eosinophils cultured with IL-15 alone or
with TNF-
and IL-4 with TNF-
(Figure 2, bottom
panel). DNA fragmentation and nuclear morphology results were highly correlated with viability (data not
shown), demonstrating that IL-15 alone or in combination with TNF-
, and IL-4 combined with TNF-
, maintained
eosinophil viability by inhibiting spontaneous apoptosis.
|
We then investigated by ELISA (sensitivities of > 7 pg/ml)
whether IL-15 and the other common
chain receptor-
sharing cytokines stimulated the production of the classic
hematopoietins, or TNF-
, from the cultured eosinophils
and hence prolonged eosinophil survival. GM-CSF, IL-5,
and TNF-
were not detected in supernatants collected at
24 and 48 h from any conditions of eosinophil culture
(data not shown). In an alternative approach to this question, neutralizing antibodies against GM-CSF, IL-3, and
IL-5 at 50 µg/ml were added to the culture immediately after the addition of IL-15. Whereas anti-IL-5 had little to
no effect on cells stimulated with IL-15, with or without
TNF-
(Figure 3), anti-GM-CSF demonstrated a significant inhibitory effect throughout 72 h, reducing the survival of IL-15-stimulated eosinophils nearly to that seen in
unstimulated eosinophils. These data suggest that IL-15
stimulated eosinophils to secrete small amounts of GM-CSF below the detectable level of ELISA but sufficient to
prolong survival of the cells. The effect of anti-IL-3 was initially similar to that of anti-GM-CSF, suggesting an
early autocrine effect of IL-3 but, over the complete time
course, was not significantly different (P = 0.13) compared
with eosinophils stimulated with IL-15. Anti-GM-CSF,
and to a lesser extent anti-IL-3, also exhibited similar inhibition of the enhanced survival in response to combined
stimulation with TNF-
and IL-4, whereas anti-IL-5, again,
had no effect (data not shown).
|
NF-
B Activation
Recently, NF-
B, a ubiquitous transcription factor, has
been implicated in regulation of apoptosis and activation
of granulocytes (16, 26) including eosinophils (29, 30).
Furthermore, as IL-15 has been demonstrated to result in
NF-
B activation in neutrophils (26), we asked whether
this transcription factor was involved in the observed effects of IL-15 in eosinophils. Accordingly, freshly isolated
eosinophils were incubated with Bay 11-7082 at 3 µM for
30 min before the addition of cytokines. Although Bay 11-
7082 (an inhibitor of I
B phosphorylation) at 3 µM alone
did not alter survival of unstimulated eosinophils at 24, 48, or 72 h, it completely inhibited the prosurvival effect of
IL-15 (Figure 4A). Furthermore, a similar result was seen
when this inhibitor was used with TNF-
and IL-15 (Figure 4B) and with TNF-
and IL-4 (data not shown). Interestingly, the pro-survival effect of TNF-
alone (Figure 4C)
was converted to an enhanced apoptotic signal if NF-
B
was blocked by Bay 11-7082 (viability of 16.2 ± 5.3 versus
42 ± 8.2% for controls at 48 h, P = 0.02), confirming the
findings of Ward and colleagues (28).
|
As shown in Figure 5, eosinophils treated with Bay 11-
7082 in the presence and absence of cytokines clearly
showed increased hypodiploid DNA and pyknotic nuclei,
showing that the eosinophils had undergone apoptotic and
not necrotic cell death. Therefore, it appeared that NF-
B
activation is involved in regulation of spontaneous eosinophil apoptosis by these cytokines. Further evidence for a
link between the pro-survival effect of IL-15 and NF-
B pathways was provided by confocal microscopy (Figure 6).
Nuclear translocation of the p65 subunit, indicative of NF-
B
activation, was noticeably increased after 15-min stimulation with TNF-
, IL-15, or the combination of TNF-
and
IL-15 (or TNF-
and IL-4; data not shown) when compared with control eosinophils. Importantly, and as predicted, p65 translocation in stimulated eosinophils, under
all conditions, was inhibited by Bay 11-7082. These data further suggest that NF-
B plays a role in the reduction of
spontaneous apoptosis by IL-15, with or without TNF-
.
|
|
Because autocrine production of GM-CSF was required for the pro-survival effect of IL-15 (and TNF-
with
IL-15 or IL-4), and GM-CSF has recently been shown to
induce low levels of NF-
B nuclear translocation in eosinophils (30), we asked whether NF-
B can also act downstream of GM-CSF. Exogenous GM-CSF at 100 pg/ml
yielded comparable, prolonged survival to IL-15 (50 ng/ml),
and this pro-survival effect was also inhibited by Bay 11-
7082 (Figure 4D). However, we could detect no evidence
for p65 translocation by confocal microscopy at 5, 10, 20, 30, or 60 min following stimulation with GM-CSF up to
250 pg/ml (data not shown). Thus, while we have demonstrated that NF-
B appears to act upstream of GM-CSF
production in IL-15-stimulated eosinophils, it is also possible
that it is acting downstream of GM-CSF (see DISCUSSION).
Increased Expression of IL-15 in Airway Tissue of Asthmatic Individuals
To explore a potential role of IL-15 as a regulatory cytokine of eosinophil apoptosis in vivo, we measured IL-15 expression by immunohistochemistry in endobronchial biopsy tissues from nine subjects with moderate to severe asthma and four normal individuals. IL-15 expression in epithelial cells varied greatly among these subjects and did not reach statistical difference between subjects with asthma and control groups. Of note, however, subjects with asthma appeared to have a significantly higher number of IL-15-positive submucosal cells/mm2 than control subjects (medians of 35 [19-79, IQR] versus 19 [4-28, IQR], respectively, P < 0.05) (Figures 7A and 7B). Further investigation of the inflammatory infiltrate identified CD68+ macrophages as the predominant source of IL-15 (Figures 7C and 7D), consistent with other inflammatory infiltrates (31). Hence, our results suggest that IL-15 is present in airways of subjects with asthma and may contribute to prolonging eosinophil survival in vivo.
|
| |
Discussion |
|---|
|
|
|---|
Similar to its pro-survival effect on NK cells, T cells, and neutrophils (16), IL-15 inhibited spontaneous apoptosis of human peripheral blood eosinophils in vitro. The mechanism appeared to involve autocrine production of GM-CSF, and to a lesser extent, IL-3, but not IL-5. Although we were unable to detect GM-CSF by ELISA, the amount produced was presumably sufficient to prolong eosinophil survival as evident by blockade with neutralizing antibody to GM-CSF. This phenomenon has been reported by Esnault and colleagues where peripheral blood eosinophils successfully transfected with GM-CSF mRNA showed significantly increased survival despite undetectable secretion of GM-CSF (32). Furthermore, these investigators showed that conditioned media from the transfected eosinophils prolonged survival of nontransfected eosinophils. One possibility is that secreted GM-CSF is readily bound to its receptor and therefore unavailable to the assay. Of interest, when employing exogenous GM-CSF, a concentration of 100 pg/ml was needed in our studies to achieve comparable survival as seen with IL-15. Thus, it is conceivable that endogenously produced GM-CSF has greater biologic potency or t1/2 than recombinant protein. This may represent a unique property of GM-CSF, which appears to be the predominant pro-survival cytokine produced by eosinophils themselves (33).
We have demonstrated that activation of NF-
B is a required downstream event in the inhibition of eosinophil
apoptosis by IL-15. NF-
B plays a pivotal role in apoptosis
regulation of many cells (28, 37). The canonical form of
NF-
B is a heterodimer, which usually consists of two proteins, a p65 (RelA) subunit and a p50 subunit. Activation
of NF-
B is regulated by I
B proteins, which, in response
to stimuli, are phosphorylated, polyubiquitinated, and finally degraded by the proteasome. The released NF-
B is then allowed to enter the nucleus, where it binds to specific sequences of target genes (40). Like IL-15, TNF-
also activated NF-
B, and in keeping with previous reports, had a modest effect on inhibiting eosinophil apoptosis. Of interest, when activation of NF-
B was inhibited,
the proapoptotic effect of TNF-
on eosinophils was unmasked. This is consistent with findings from Ward and
colleagues, and supports a role for NF-
B as a pivotal regulator in eosinophil apoptosis (28).
We also investigated the effects of other common
chain receptor-sharing cytokines on eosinophil apoptosis.
IL-2, an important cytokine for T cell survival, did not alter eosinophil survival. Similar to IL-2, IL-4 by itself neither prolonged nor enhanced spontaneous eosinophil survival. These findings are in contrast to a previous report by
Wedi and colleagues, which showed that IL-4 alone enhanced spontaneous eosinophil apoptosis (34). We were
unable to reproduce this result using the same concentrations of IL-4. This discrepancy might be due to the difference in the in vivo environment of eosinophils harvested
for each study, i.e., normal donors by Wedi and colleagues
and donors with allergies here. However, we found that
when combined with TNF-
, IL-4 significantly enhanced
eosinophil viability, and this synergism is the focus of ongoing investigation. Similar to IL-15, the pro-survival effect of IL-4 combined with TNF-
appeared to be mediated
through the autocrine production of GM-CSF and dependent upon NF-
B activation. Although the presence of the
individual chains of each cytokine receptor, i.e., IL-2R
,
IL-2R
, IL-4R
, and IL-9R
, has been established for
eosinophils, IL-15R
expression, which is required for IL-15 high-affinity binding (13, 41, 42), awaits availability of appropriate reagents. However, since IL-15 shares the 
receptors with IL-2, and in view of the differential effects of
IL-15 and IL-2 on eosinophils, our results support the existence of IL-15R
on human eosinophils and the importance of IL-15 as a member of this cytokine family that can
by itself prolong eosinophil survival.
One set of target genes, which might be involved in this
antiapoptotic pathway induced by IL-15, are those of the
Bcl-2 family. Salmon and colleagues have shown that synovial T cells exposed to IL-15 in vitro showed upregulation
of Bcl-2 and Bcl-XL resulting in decreased spontaneous
apoptosis of these cells (18). The roles of these Bcl-2 family proteins in eosinophil apoptosis have been studied by
others, although the results from these studies have been
inconclusive. Although it appears that GM-CSF can upregulate the expression of Bcl-XL/S and Bcl-2 in eosinophils (43), we were unable to show that IL-15 modulated these members of Bcl-2 family proteins (data not
shown), perhaps due to insensitivity of the assay. Alternatively, it is conceivable that IL-15 stimulation involves another yet to be identified anti-apoptotic protein in eosinophils such as A1, which, along with Bcl-X, are potential NF-
B-dependent candidates. Whether the expression of
A1 in eosinophils can be induced by prosurvival cytokines
has not yet been studied and deserves further exploration.
We have shown that autocrine production of GM-CSF
and NF-
B activation are required for IL-15 to prolong
eosinophil survival, and thus our data are concordant with
earlier demonstrations of NF-
B-mediated regulation of
GM-CSF transcription (46, 47). From our data, it is, however, unclear whether GM-CSF itself activates NF-
B as a
downstream event in eosinophils. Although the inhibitor Bay 11-7082 inhibited the prosurvival effect of GM-CSF
at 48 and 72 h, we were unable to demonstrate p65 translocation by confocal microscopy, perhaps because of sensitivity or timing of the assay. Further, we note that data
using EMSA has shown very low levels of NF-
B translocation in eosinophils stimulated with GM-CSF (10 ng/ml
for 30 minutes) (30). In neutrophils, GM-CSF has been shown to activate the PI 3-kinase/Akt pathway, resulting
in delayed apoptosis (48). Recent studies suggest that Akt
is activated in blood eosinophils isolated from allergic
donors (49) perhaps explaining why PI3 kinase inhibitors
do not enhance eosinophil apoptosis (21) (and indeed
have no effect on eosinophils stimulated with IL-15; data
not shown). Alternatively, Akt can also be activated independently of PI3 kinase (50), suggesting an alternative pathway for Akt to promote eosinophil survival. Interestingly, Akt has recently been shown to activate NF-
B via
activation of I
B
degradation (51, 52). Therefore, we
speculate that in addition to mediating IL-15-induced autocrine production of GM-CSF as our data indicates, NF-
B
may also be activated downstream following GM-CSF activation of Akt.
Lastly, the presence of IL-15 in vivo was explored in a
pilot study of subjects with mostly severe asthma. Although the epithelial staining for IL-15 varied greatly
among both control and asthmatic individuals, the submucosa of the asthmatic group had a significantly higher
number of positively stained cells, predominantly CD68+
macrophages, compared with control subjects. Although
many questions are raised by these preliminary data regarding both disease severity and the effects of medications on IL-15 expression, these data, along with initial reports associating IL-15 with Th2 inflammation (21, 22)
suggest a role for IL-15 as an eosinophil pro-survival cytokine in asthmatic tissue. Collectively, we propose that IL-15 plays a role in allergic diseases by inhibiting eosinophil
apoptosis and that its anti-apoptotic effects appear to be
mediated through autocrine production of GM-CSF and
ultimately by NF-
B activation.
| |
Footnotes |
|---|
Address correspondence to: Donna L. Bratton, M.D., Department of Pediatrics, D506, National Jewish Medical and Research Center, Denver, CO 80206. E-mail: brattond{at}njc.org
(Received in original form January 29, 2001 and in revised form December 17, 2001).
Abbreviations: Bay 11, Bay 11-7082; granulocyte macrophage-colony stimulating factor, GM-CSF; inhibitory protein, I
B NF-
B; interleukin,
IL; interquartile range, IQR; nuclear factor-
B, NF-
B; standard error of
the mean, SEM; sodium dodecyl sulfate-polyacrylamide gel electrophoresis, SDS-PAGE; T helper cells, type 2, Th2.
Acknowledgments: The authors wish to thank Ms. Jenai Kailey and Ms. Cally Duncan for their technical assistance and Ms. Brenda Sebern for preparation of the manuscript. Patrick McDonald is a Scholar of the Canadian Institutes for Health Research. This manuscript has been supported by National Institutes of Health grants HL34303 and HL60980.
| |
References |
|---|
|
|
|---|
1. Simon, H. U., S. Yousefi, C. Schranz, A. Schapowal, C. Bachert, and K. Blaser. 1997. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J. Immunol. 158: 3902-3908 [Abstract].
2. Vignola, A. M., P. Chanez, G. Chiappara, L. Siena, A. Merendino, C. Reina, R. Gagliardo, M. Profita, J. Bousquet, and G. Bonsignore. 1999. Evaluation of apoptosis of eosinophils, macrophages, and T lymphocytes in mucosal biopsy specimens of patients with asthma and chronic bronchitis (see comments). J. Allergy Clin. Immun. 103: 563-573 [Medline].
3. Woolley, K. L., P. G. Gibson, K. Carty, A. J. Wilson, S. H. Twaddell, and M. J. Woolley. 1996. Eosinophil apoptosis and the resolution of airway inflammation in asthma. Am. J. Respir. Crit. Care Med. 154: 237-243 [Abstract].
4. Her, E., J. Frazer, K. F. Austen, and W. F. Owen Jr.. 1991. Eosinophil hematopoietins antagonize the programmed cell death of eosinophils: cytokine and glucocorticoid effects on eosinophils maintained by endothelial cell-conditioned medium. J. Clin. Invest. 88: 1982-1987 .
5.
Yamaguchi, Y.,
T. Suda,
S. Ohta,
K. Tominaga,
Y. Miura, and
T. Kasahara.
1991.
Analysis of the survival of mature human eosinophils: interleukin-5
prevents apoptosis in mature human eosinophils.
Blood
78:
2542-2547
6. Yousefi, S., K. Blaser, and H. U. Simon. 1997. Activation of signaling pathways and prevention of apoptosis by cytokines in eosinophils. Int. Arch. Allergy Immunol. 112: 9-12 [Medline].
7.
Coffer, P. J.,
R. C. Schweizer,
G. R. Dubois,
T. Maikoe,
J. W. Lammers, and
L. Koenderman.
1998.
Analysis of signal transduction pathways in human
eosinophils activated by chemoattractants and the T-helper 2-derived cytokines interleukin-4 and interleukin-5.
Blood
91:
2547-2557
8.
Pazdrak, K.,
B. Olszewska-Pazdrak,
S. Stafford,
R. P. Garofalo, and
R. Alam.
1998.
Lyn, Jak2, and Raf-1 kinases are critical for the antiapoptotic
effect of interleukin 5, whereas only Raf-1 kinase is essential for eosinophil
activation and degranulation.
J. Exp. Med.
188:
421-429
9. Daffern, P. J., M. A. Jagels, J. J. Saad, W. Fischer, and T. E. Hugli. 1999. Upper airway epithelial cells support eosinophil survival in vitro through production of GM-CSF and prostaglandin E2: regulation by glucocorticoids and TNF-alpha. Allergy Asthma Proc. 20: 243-253 [Medline].
10. Zhang, S., Q. Mohammed, A. Burbidge, C. M. Morland, and W. R. Roche. 1996. Cell cultures from bronchial subepithelial myofibroblasts enhance eosinophil survival in vitro. Eur. Respir. J. 9: 1839-1846 [Abstract].
11. Broide, D. H., M. M. Paine, and G. S. Firestein. 1992. Eosinophils express interleukin 5 and granulocyte macrophage colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics. J. Clin. Invest. 90: 1414-1424 .
12. Wedi, B., U. Raap, H. Lewrick, and A. Kapp. 1998. IL-4-induced apoptosis in peripheral blood eosinophils. J. Allergy Clin. Immunol. 102: 1013-1020 [Medline].
13. Nutka, E., A. Soussi-Gounni, A. Hazcku, K. Holroyd, N. Nicolaides, R. Levitt, and Q. Hamid. 1999. Stimulation of IL-9 receptors on human eosinophils upregulates IL-5 receptor mRNA expression. J. Allergy Clin. Immunol. 103: S113 .
14. Luttmann, W., B. Knoechel, M. Foerster, H. Matthys, J. C. Virchow Jr., and C. Kroegel. 1996. Activation of human eosinophils by IL-13. Induction of CD69 surface antigen, its relationship to messenger RNA expression, and promotion of cellular viability. J. Immunol. 157: 1678-1683 [Abstract].
15. Carson, W. E., T. A. Fehniger, S. Haldar, K. Eckhert, M. J. Lindemann, C. F. Lai, C. M. Croce, H. Baumann, and M. A. Caligiuri. 1997. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J. Clin. Invest. 99: 937-943 [Medline].
16.
Girard, D.,
M. E. Paquet,
R. Paquin, and
A. D. Beaulieu.
1996.
Differential
effects of interleukin-15 (IL-15) and IL-2 on human neutrophils: modulation of phagocytosis, cytoskeleton rearrangement, gene expression, and
apoptosis by IL-15.
Blood
88:
3176-3184
17.
Lai, Y. G.,
V. Gelfanov,
V. Gelfanova,
L. Kulik,
C. L. Chu,
S. W. Jeng, and
N. S. Liao.
1999.
IL-15 promotes survival but not effector function differentiation of CD8+ TCR
+ intestinal intraepithelial lymphocytes.
J. Immunol.
163:
5843-5850
18. Salmon, M., D. Scheel-Toellner, A. P. Huissoon, D. Pilling, N. Shamsadeen, H. Hyde, A. D. D'Angeac, P. A. Bacon, P. Emery, and A. N. Akbar. 1997. Inhibition of T cell apoptosis in the rheumatoid synovium. J. Clin. Invest. 99: 439-446 [Medline].
19. Kennedy, M. K., and L. S. Park. 1996. Characterization of interleukin-15 (IL-15) and the IL-15 receptor complex. J. Clin. Immunol. 16: 134-143 [Medline].
20.
Fehniger, T. A.,
M. H. Shah,
M. J. Turner,
J. B. VanDeusen,
S. P. Whitman,
M. A. Cooper,
K. Suzuki,
M. Wechser,
F. Goodsaid, and
M. A. Caligiuri.
1999.
Differential cytokine and chemokine gene expression by human NK
cells following activation with IL-18 or IL-15 in combination with IL-12:
implications for the innate immune response.
J. Immunol.
162:
4511-4520
21. Mori, A., M. Suko, O. Kaminuma, S. Inoue, T. Ohmura, Y. Nishizaki, T. Nagahori, Y. Asakura, A. Hoshino, Y. Okumura, G. Sato, K. Ito, and H. Okudaira. 1996. IL-15 promotes cytokine production of human T helper cells. J. Immunol. 156: 2400-2405 [Abstract].
22.
Means-Markwell, M.,
T. Burgess,
D. deKeratry,
K. O'Neil,
J. Mascola,
T. Fleisher, and
D. Lucey.
2000.
Eosinophilia with aberrant T cells and elevated serum levels of interleukin-2 and interleukin-15.
N. Engl. J. Med.
342:
1568-1571
23. Thomassen, M. J., B. Raychaudhuri, R. A. Dweik, C. Farver, L. Buhrow, A. Malur, M. J. Connors, J. Drazba, J. Hammel, S. C. Erzurum, and M. S. Kavuru. 1999. Nitric oxide regulation of asthmatic airway inflammation with segmental allergen challenge. J. Allergy Clin. Immunol. 104: 1174-1182 [Medline].
24.
Dewson, G.,
G. M. Cohen, and
A. J. Wardlaw.
2001.
Interleukin-5 inhibits
translocation of Bax to the mitochondria, cytochrome c release, and activation of caspases in human eosinophils.
Blood
98:
2239-2247
25. Valerius, T., R. Repp, J. R. Kalden, and E. Platzer. 1990. Effects of IFN on human eosinophils in comparison with other cytokines: a novel class of eosinophil activators with delayed onset of action. J. Immunol. 145: 2950-2958 [Abstract].
26.
McDonald, P. P.,
M. P. Russo,
S. Ferrini, and
M. A. Cassatella.
1998.
Interleukin-15 (IL-15) induces NF-kappaB activation and IL-8 production in
human neutrophils.
Blood
92:
4828-4835
27.
McDonald, P. P.,
A. Bald, and
M. A. Cassatella.
1997.
Activation of the NF-kappaB pathway by inflammatory stimuli in human neutrophils.
Blood
89:
3421-3433
28.
Ward, C.,
E. R. Chilvers,
M. F. Lawson,
J. G. Pryde,
S. Fujihara,
S. N. Farrow,
C. Haslett, and
A. G. Rossi.
1999.
NF-kappaB activation is a critical
regulator of human granulocyte apoptosis in vitro.
J. Biol. Chem.
274:
4309-4318
29. Olszewska-Pazdrak, B., K. Pazdrak, A. Brasier, and R. Garafalo. 2000. Activation of the transcription factor NF-kappa B in human eosinophils: role in RSV mediated RANTES production. J. Allergy Clin. Immunol. 106: S170-S171 .
30. Yamashita, N., H. Koizumi, M. Murata, K. Mano, and K. Ohta. 1999. Nuclear factor kappa B mediates interleukin-8 production in eosinophils. Int. Arch. Allergy Immunol. 120: 230-236 [Medline].
31.
Liu, Z.,
K. Geboes,
S. Colpaert,
G. R. D'Haens,
P. Rutgeerts, and
J. L. Ceuppens.
2000.
IL-15 is highly expressed in inflammatory bowel disease
and regulates local T cell-dependent cytokine production.
J. Immunol.
164:
3608-3615
32.
Esnault, S., and
J. S. Malter.
1999.
Primary peripheral blood eosinophils
rapidly degrade transfected granulocyte-macrophage colony-stimulating
factor mRNA.
J. Immunol.
163:
5228-6234
33.
Meerschaert, J.,
R. F. Vrtis,
Y. Shikama,
J. B. Sedgwick,
W. W. Busse, and
D. F. Mosher.
1999.
Engagement of
4
7 integrins by monoclonal antibodies or ligands enhances survival of human eosinophils in vitro.
J. Immunol.
163:
6217-6227
34. Wedi, B., U. Raap, H. Lewrick, and A. Kapp. 1997. Delayed eosinophil programmed cell death in vitro: a common feature of inhalant allergy and extrinsic and intrinsic atopic dermatitis. J. Allergy Clin. Immunol. 100: 536-543 [Medline].
35.
Iversen, P. O.,
D. Robinson,
S. Ying,
Q. Meng,
A. B. Kay,
I. Clark-Lewis, and
A. F. Lopez.
1997.
The GM-CSF analogue E21R induces apoptosis of normal
and activated eosinophils.
Am. J. Respir. Crit. Care Med.
156:
1628-1632
36.
Kim, J. T.,
A. W. Schimming, and
H. Kita.
1999.
Ligation of Fc gamma RII
(CD32) pivotally regulates survival of human eosinophils.
J. Immunol.
162:
4253-4259
37.
Baichwal, V. R., and
P. A. Baeuerle.
1997.
Activate NF-
B or die?
Curr.
Biol.
7:
R94-R96
[Medline].
38.
Beg, A. A., and
D. Baltimore.
1996.
An essential role for NF-
B in preventing TNF- -
-induced cell death(see comments).
Science
274:
782-784
39. Van Antwerp, D. J., S. J. Martin, T. Kafri, D. R. Green, and I. M. Verma. 1996. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 274:787-789. (see comments)
40. Baeuerle, P. A.. 1998. IkappaB-NF-kappaB structures: at the interface of inflammation control (comment). Cell 95: 729-731 [Medline].
41.
Dubois, G. R.,
R. C. Schweizer,
C. Versluis,
C. A. Bruijnzeel-Koomen, and
P. L. Bruijnzeel.
1998.
Human eosinophils constitutively express a functional interleukin-4 receptor: interleukin-4 -induced priming of chemotactic responses and induction of PI-3 kinase activity.
Am. J. Respir. Cell Mol.
Biol.
19:
691-699
42. Plumas, J., V. Gruart, D. Aldebert, M. J. Truong, M. Capron, A. Capron, and L. Prin. 1991. Human eosinophils from hypereosinophilic patients spontaneously express the p55 but not the p75 interleukin 2 receptor subunit. Eur. J. Immunol. 21: 1265-1270 [Medline].
43.
Dewson, G.,
G. M. Walsh, and
A. J. Wardlaw.
1999.
Expression of Bcl-2
and its homologues in human eosinophils: modulation by interleukin-5.
Am. J. Respir. Cell Mol. Biol.
20:
720-728
44.
Dibbert, B.,
I. Daigle,
D. Braun,
C. Schranz,
M. Weber,
K. Blaser,
U. Zangemeister-Wittke,
A. N. Akbar, and
H. U. Simon.
1998.
Role for
Bcl-xL in delayed eosinophil apoptosis mediated by granulocyte-macrophage colony-stimulating factor and interleukin-5.
Blood
92:
778-783
45.
Druilhe, A.,
M. Arock,
L. Le Goff, and
M. Pretolani.
1998.
Human eosinophils express bcl-2 family proteins: modulation of Mcl-1 expression by
IFN-gamma.
Am. J. Respir. Cell Mol. Biol.
18:
315-322
46.
Schreck, R., and
P. A. Baeuerle.
1990.
NF-kappa B as inducible transcriptional activator of the granulocyte- macrophage colony-stimulating factor
gene.
Mol. Cell. Biol.
10:
1281-1286
47.
Dunn, S. M.,
L. S. Coles,
R. K. Lang,
S. Gerondakis,
M. A. Vadas, and
M. F. Shannon.
1994.
Requirement for nuclear factor (NF)-kappa B p65 and NF-interleukin-6 binding elements in the tumor necrosis factor response region of
the granulocyte colony-stimulating factor promoter.
Blood
83:
2469-2479
48.
Klein, J. B.,
M. J. Rane,
J. A. Scherzer,
P. Y. Coxon,
R. Kettritz,
J. M. Mathiesen,
A. Buridi, and
K. R. McLeish.
2000.
Granulocyte-macrophage
colony-stimulating factor delays neutrophil constitutive apoptosis through
phosphoinositide 3-kinase and extracellular signal-regulated kinase pathways.
J. Immunol.
164:
4286-4291
49.
Bracke, M.,
E. van de Graaf,
J. W. Lammers,
P. J. Coffer, and
L. Koenderman.
2000.
In vivo priming of FcalphaR functioning on eosinophils of allergic asthmatics.
J. Leukoc. Biol.
68:
655-661
50. Kandel, E. S., and N. Hay. 1999. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp. Cell Res. 253: 210-229 [Medline].
51. Kane, L. P., V. S. Shapiro, D. Stokoe, and A. Weiss. 1999. Induction of NF-kappaB by the Akt/PKB kinase. Curr. Biol. 9: 601-604 [Medline].
52.
Yang, C. H.,
A. Murti,
S. R. Pfeffer,
J. G. Kim,
D. B. Donner, and
L. M. Pfeffer.
2001.
Interferon alpha /beta promotes cell survival by activating
nuclear factor kappa B through phosphatidylinositol 3-kinase and Akt.
J.
Biol. Chem.
276:
13756-13761
This article has been cited by other articles:
![]() |
M. Martinez-Losa, J. Cortijo, G. Juan, M. Ramon, M. J. Sanz, and E. J. Morcillo Modulatory effects of N-acetyl-L-cysteine on human eosinophil apoptosis Eur. Respir. J., September 1, 2007; 30(3): 436 - 442. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Matsuyama, H. Mitsuyama, M. Ono, Y. Shirahama, I. Higashimoto, M. Osame, and K. Arimura Discoidin domain receptor 1 contributes to eosinophil survival in an NF-{kappa}B-dependent manner in Churg-Strauss syndrome Blood, January 1, 2007; 109(1): 22 - 30. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Wimmer, S. K. Khaldoyanidi, M. Judex, N. Serobyan, R. G. DiScipio, and I. U. Schraufstatter CCL18/PARC stimulates hematopoiesis in long-term bone marrow cultures indirectly through its effect on monocytes Blood, December 1, 2006; 108(12): 3722 - 3729. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Pelletier and D. Girard Differential Effects of IL-15 and IL-21 in Myeloid (CD11b+) and Lymphoid (CD11b-) Bone Marrow Cells J. Immunol., July 1, 2006; 177(1): 100 - 108. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. El Bakkouri, A. Wullaert, M. Haegman, K. Heyninck, and R. Beyaert Adenoviral Gene Transfer of the NF-{kappa}B Inhibitory Protein ABIN-1 Decreases Allergic Airway Inflammation in a Murine Asthma Model J. Biol. Chem., May 6, 2005; 280(18): 17938 - 17944. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ruckert, K. Brandt, A. Braun, H.-G. Hoymann, U. Herz, V. Budagian, H. Durkop, H. Renz, and S. Bulfone-Paus Blocking IL-15 Prevents the Induction of Allergen-Specific T Cells and Allergic Inflammation In Vivo J. Immunol., May 1, 2005; 174(9): 5507 - 5515. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-T. Walsh, D. R. Curran, P. J. Kingham, R. K. Morgan, N. Durcan, G. J. Gleich, W. G. McLean, and R. W. Costello Effect of Eosinophil Adhesion on Intracellular Signaling in Cholinergic Nerve Cells Am. J. Respir. Cell Mol. Biol., March 1, 2004; 30(3): 333 - 341. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Esnault and J. S. Malter Hyaluronic Acid or TNF-{alpha} Plus Fibronectin Triggers Granulocyte Macrophage-Colony-Stimulating Factor mRNA Stabilization in Eosinophils Yet Engages Differential Intracellular Pathways and mRNA Binding Proteins J. Immunol., December 15, 2003; 171(12): 6780 - 6787. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. L. Ahren, E. Eriksson, A. Egesten, and K. Riesbeck Nontypeable Haemophilus |